TICKERNERD
Menu
BLCOBLCOHealthcare · Medical Instruments & Supplies

BLCO Stock Forecast: Bausch + Lomb Corp. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$17
+3.87% on the day

The 15 Wall Street analysts covering Bausch + Lomb Corp. hold a median 12-month price target of $19 — +15.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.7B
Ticker Nerd rank
90 / 100
Median analyst target
$19
Analysts covering
15
Revenue$1.4B+9.1% y/y
Operating income$108.0M
Net income−$10.0M
Free cash flow$82.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−3.3%
YTD
−2.5%
1Y
+11.3%
From 52W high
−10.4%
From 52W low
+14.4%
$15
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BLCO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bausch + Lomb Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
93
Quality
88
Growth
80
Accruals
69
Revisions
69
Momentum
65
Issuance
42
Size
21

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLCO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLCO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$14$16$18$20$22$24Jan 26Apr 26Jul 26Oct 26BLCOHigh $24Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
7 Buy7 Hold1 Sell
Low $16Median $19High $24

The green dot is the last close — the median target sits +15.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Oct 2026BarclaysInitiatesOverweight$24
15 Sept 2026NeedhamReiteratesHold—
15 Sept 2026NeedhamReiteratesHold—
9 Sept 2026Leerink PartnersInitiatesOutperform$24
9 Sept 2026Leerink PartnersInitiatesOutperform—
28 Aug 2026HC Wainwright & Co.ReiteratesBuy$21
28 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $21
30 July 2026UBSMaintainsBuy$21 → $23
30 July 2026UBSMaintainsBuy—
28 July 2026UBSInitiatesBuy—
28 July 2026UBSInitiatesBuy$21
8 July 2026CitigroupMaintainsBuy—
6 July 2026Evercore ISI GroupMaintainsIn-Line—
6 July 2026Evercore ISI GroupMaintainsIn-Line$16 → $17
30 Apr 2026CitigroupMaintainsBuy—
30 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLCO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BLCO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, Bausch + Lomb Corp. returned +11.3% against +17.3% for the S&P 500, dividends included.

BLCO vs S&P 500, last 12 monthsTotal return, rebased to 100
100105110115120125Jan 26Apr 26Jul 26Oct 26BLCOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLCO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.4%
Analysts raising
8
Analysts cutting
2
Fundamentals

Bausch + Lomb Corp. (BLCO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.7×

Cheaper than 95% of US stocks

Price / sales
1.1×

Cheaper than 66% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
12.9×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
9.1%

Higher than 49% of US stocks

Earnings growth (YoY)
9.1%

Higher than 47% of US stocks

Gross margin
62.2%

Higher than 75% of US stocks

Operating margin
7.7%

Higher than 60% of US stocks

Net margin
−3.2%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−2.5%

Higher than 42% of US stocks

Return on assets
1.8%

Higher than 58% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bausch + Lomb Corp. (BLCO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bausch + Lomb Corp. has a market value of $5.7B and an enterprise value of $10.5B.

  • Revenue in the twelve months to 30 June 2026: $5.3B. The latest quarter grew 9.1% year on year.

  • Net income over the same four quarters: −$163.0M, a −3.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.48.

  • Free cash flow in the twelve months to 30 June 2026: $137.0M.

  • Shares outstanding: 357.1M.

  • Trailing P/E: −15.7×; forward P/E: 14.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Bausch + Lomb Corp. employs 13,000 people — $410K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

BLCO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BLCOBausch + Lomb Corp.$5.7B
90
TFXTeleflex, Inc.$5.4B
77
STVNStevanato Group SpA$5.3B
67
MMSIMerit Medical Systems, Inc.$5.2B
91
MMEDMiniMed Group, Inc.$4.7B
1
ATRAptarGroup, Inc.$7.9B
49
ICUIICU Medical, Inc.$4.0B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bausch + Lomb Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLCO news & analysis

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Business Wire · 12 Oct 2026positive

Bausch + Lomb appointed board chairman Thomas J. Appio interim CEO, effective immediately. Appio will continue as CEO of parent Bausch Health, and the headline says the companies expect to raise full-year 2026 guidance.

Why it matters — BLCO watchers may be interested in the leadership change and the stated expectation of higher full-year 2026 guidance.

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Business Wire · 6 Oct 2026positive

Bausch + Lomb said it made progress developing BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration, after a constructive meeting with the FDA. The meeting provided greater clarity on the candidate’s clinical development path.

Why it matters — The update gives BLCO watchers information about the regulatory discussion shaping development of the company’s investigational dry AMD treatment.

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

Business Wire · 5 Oct 2026neutral

Bausch + Lomb announced it will release its third-quarter 2026 financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update, with materials available on its Investor Relations website beforehand.

Why it matters — A BLCO watcher would care because the release date and webcast offer a scheduled opportunity to review the company's latest quarterly performance and business update.

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Zacks Investment Research · 14 Sept 2026positive

Bausch + Lomb has received European CE Mark approval for its next-generation SeeLyra femtosecond laser, a compact platform designed for cataract and corneal procedures. This approval expands the company's surgical portfolio in Europe.

Why it matters — BLCO watchers would care because the CE Mark approval extends the company's surgical product lineup into the European market, potentially broadening its revenue opportunities in ophthalmology.

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Business Wire · 11 Sept 2026positive

Bausch + Lomb announced European CE Mark approval of its SeeLyra femtosecond laser, a compact platform designed for precision in laser preparation for premium cataract, LASIK flap, and corneal therapeutic surgeries.

Why it matters — The regulatory approval expands BLCO's availability of its next-generation femtosecond laser in European markets, broadening its surgical product portfolio.

FAQ

Frequently asked questions about BLCO stock

What is the BLCO stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Bausch + Lomb Corp. have a median 12-month price target of $19, with estimates ranging from $16 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLCO stock a buy right now?

Of the 15 analysts covering Bausch + Lomb Corp., 7 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bausch + Lomb Corp. 90 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLCO?

As at 14 Oct 2026, Bausch + Lomb Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BLCO stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +15.5% from the last close, and Ticker Nerd's factor model ranks Bausch + Lomb Corp. 90 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLCO stock forecast for 2030?

No analyst covering Bausch + Lomb Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $24 over the next 12 months.

How has BLCO stock performed over the past year?

Bausch + Lomb Corp. returned +11.3% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bausch + Lomb Corp. do?

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions.

What is the latest news on BLCO?

The most recent item we track (Business Wire, 12 Oct 2026): "Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance". Bausch + Lomb appointed board chairman Thomas J. Appio interim CEO, effective immediately. Appio will continue as CEO of parent Bausch Health, and the headline says the companies expect to raise full-year 2026 guidance.

Company

About Bausch + Lomb Corp.

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions. Its surgical portfolio includes intraocular lenses, ophthalmic surgical devices, and instruments used in cataract and other eye procedures. The company serves consumers, eye care professionals, and healthcare providers across international markets, supporting routine vision maintenance as well as more specialized clinical treatment. Headquartered in Vaughan, Ontario, Canada, Bausch + Lomb focuses exclusively on eye health and remains a recognized name in the medical devices and ophthalmic goods industry.

CEO Mr. Brenton L. Saunders J.D. · 13,000 employees · Canada · https://www.bausch.com